Gemma Castaño-Vinyals

Dr. Gemma Castaño-Vinyals

ISGlobal
+3
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FSFredrick Schumacher
Fredrick Schumacher
AOAli Amin Al Olama
Ali Amin Al Olama
SBSonja I. Berndt
Sonja I. Berndt
SBSara Benlloch
Sara Benlloch
MAMahbubl Ahmed
Mahbubl Ahmed
C(Cancer Of The Prostate In Sweden (Caps)
Cancer Of The Prostate In Sweden (Caps)
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10−8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10−9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10−9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55–2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04–6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

1 August 2005 in The Lancet
Verified
Journal Article
Closed access
MGMontserrat García-Closas
Montserrat García-Closas
NMNuria Malats
Nuria Malats
DSDebra Silverman
Debra Silverman
MDMustafa Dosemeci
Mustafa Dosemeci
MKManolis Kogevinas
Manolis Kogevinas
NRNathaniel Rothman
Nathaniel Rothman

27 September 2006 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Cristina VillanuevaCristina Villanueva
Cristina Villanueva
KCKenneth P. Cantor
Kenneth P. Cantor
Joan GrimaltJoan Grimalt
Joan Grimalt
NMNuria Malats
Nuria Malats
DSDebra Silverman
Debra Silverman
MKManolis Kogevinas
Manolis Kogevinas
Bladder cancer has been associated with exposure to chlorination by-products in drinking water, and experimental evidence suggests that exposure also occurs through inhalation and dermal absorption. The authors examined whether bladder cancer risk was associated with exposure to trihalomethanes (THMs) through ingestion of water and through inhalation and dermal absorption during showering, bathing, and swimming in pools. Lifetime personal information on water consumption and water-related habits was collected for 1,219 cases and 1,271 controls in a 1998–2001 case-control study in Spain and was linked with THM levels in geographic study areas. Long-term THM exposure was associated with a twofold bladder cancer risk, with an odds ratio of 2.10 (95% confidence interval: 1.09, 4.02) for average household THM levels of >49 versus ≤8 μg/liter. Compared with subjects not drinking chlorinated water, subjects with THM exposure of >35 μg/day through ingestion had an odds ratio of 1.35 (95% confidence interval: 0.92, 1.99). The odds ratio for duration of shower or bath weighted by residential THM level was 1.83 (95% confidence interval: 1.17, 2.87) for the highest compared with the lowest quartile. Swimming in pools was associated with an odds ratio of 1.57 (95% confidence interval: 1.18, 2.09). Bladder cancer risk was associated with long-term exposure to THMs in chlorinated water at levels regularly occurring in industrialized countries.

4 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DCDavid V. Conti
David V. Conti
BDBurcu F. Darst
Burcu F. Darst
LMLilit C. Moss
Lilit C. Moss
ESEdward J. Saunders
Edward J. Saunders
XSXin Sheng
Xin Sheng
CHChristopher A. Haiman
Christopher A. Haiman

20 October 2010 in Occupational and Environmental Medicine
Verified
Journal Article
Closed access
PDF file
RSRichard G Stevens
Richard G Stevens
JHJohnni Hansen
Johnni Hansen
GCGiovanni Costa
Giovanni Costa
EHErhard Haus
Erhard Haus
TKTimo Kauppinen
Timo Kauppinen
KSKurt Straif
Kurt Straif
Based on the idea that electric light at night might account for a portion of the high and rising risk of breast cancer worldwide, it was predicted long ago that women working a non-day shift would be at higher risk compared with day-working women. This hypothesis has been extended more recently to prostate cancer. On the basis of limited human evidence and sufficient evidence in experimental animals, in 2007 the International Agency for Research on Cancer (IARC) classified ‘shift work that involves circadian disruption’ as a probable human carcinogen, group 2A. A limitation of the epidemiological studies carried out to date is in the definition of ‘shift work.’ IARC convened a workshop in April 2009 to consider how ‘shift work’ should be assessed and what domains of occupational history need to be quantified for more valid studies of shift work and cancer in the future. The working group identified several major domains of non-day shifts and shift schedules that should be captured in future studies: (1) shift system (start time of shift, number of hours per day, rotating or permanent, speed and direction of a rotating system, regular or irregular); (2) years on a particular non-day shift schedule (and cumulative exposure to the shift system over the subject's working life); and (3) shift intensity (time off between successive work days on the shift schedule). The group also recognised that for further domains to be identified, more research needs to be conducted on the impact of various shift schedules and routines on physiological and circadian rhythms of workers in real-world environments.

1 November 2010 in Environmental Health Perspectives
Verified
Journal Article
Open access
KCKenneth P. Cantor
Kenneth P. Cantor
Cristina VillanuevaCristina Villanueva
Cristina Villanueva
DSDebra T. Silverman
Debra T. Silverman
JFJonine D. Figueroa
Jonine D. Figueroa
FRFrancisco X Real
Francisco X Real
MKManolis Kogevinas
Manolis Kogevinas
BackgroundBladder cancer has been linked with long-term exposure to disinfection by-products (DBPs) in drinking water.ObjectivesIn this study we investigated the combined influence of DBP exposure and polymorphisms in glutathione S-transferase (GSTT1, GSTZ1) and cytochrome P450 (CYP2E1) genes in the metabolic pathways of selected by-products on bladder cancer in a hospital-based case–control study in Spain.MethodsAverage exposures to trihalomethanes (THMs; a surrogate for DBPs) from 15 years of age were estimated for each subject based on residential history and information on municipal water sources among 680 cases and 714 controls. We estimated effects of THMs and GSTT1, GSTZ1, and CYP2E1 polymorphisms on bladder cancer using adjusted logistic regression models with and without interaction terms.ResultsTHM exposure was positively associated with bladder cancer: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were 1.2 (0.8–1.8), 1.8 (1.1–2.9), and 1.8 (0.9–3.5) for THM quartiles 2, 3, and 4...